Plain-English translation of NCT05384626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called designed to target cancer cells with a specific genetic change called an ALK mutation. The study includes people with advanced lung cancer and other solid tumors who have this mutation, including those whose cancer has stopped responding to other ALK-targeting drugs. Researchers are trying to find the right dose and learn how well this medication works against different types of ALK-driven cancers.
Many patients with ALK-mutated cancers eventually stop responding to existing ALK-targeting treatments, leaving them with limited options. This new medication is being developed to help patients whose cancers have become resistant to current drugs, and to potentially offer a better treatment path for those newly diagnosed with ALK mutations.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily at home. Your participation involves regular visits to the clinic for blood tests, scans, and check-ins to monitor how your cancer is responding and how well you're tolerating the treatment. Depending on which study group you're in, you may also participate in additional visits to study how this medication interacts with other common medications. The trial is still recruiting, so the exact duration of your involvement would be discussed with the research team at enrollment.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
United States